SEC Filings

Form Description Filing date View
8-K/A

Amendment to a previously filed 8-K

View HTML
424B3

Form of prospectus reflecting facts events constituting substantive change from last form

View HTML
SC 13G

A statement of beneficial ownership of common stock by certain persons

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
S-8

Securities offered to employees pursuant to employee benefit plans

View HTML
POS AM

Post-effective amendment to an S-Type filing

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML
SC 13D/A

An amendment to a SC 13D filing

View HTML
424B3

Form of prospectus reflecting facts events constituting substantive change from last form

View HTML

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline